Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Cash (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Change in Cash for 10 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 95.02% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$34.8 million, a 219.14% decrease, with the full-year FY2025 number at -$34.8 million, down 219.14% from a year prior.
  • Change in Cash was $2.1 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$83.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $108.2 million in Q2 2024 to a low of -$114.1 million in Q3 2024.
  • A 5-year average of -$2.3 million and a median of -$1.2 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: crashed 193.4% in 2023, then skyrocketed 1697.11% in 2024.
  • Rhythm Pharmaceuticals' Change in Cash stood at -$33.1 million in 2021, then crashed by 73.32% to -$57.4 million in 2022, then soared by 92.14% to -$4.5 million in 2023, then skyrocketed by 1022.38% to $41.6 million in 2024, then plummeted by 95.02% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Change in Cash are $2.1 million (Q4 2025), -$83.4 million (Q3 2025), and $29.6 million (Q2 2025).